NAFLD

March 3, 2018

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Sirolimus, an immunosuppressant and longevity promoter, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 3/March/2018, 8.38 am

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to […]
February 25, 2018

Natural product-based therapy for Non-alcoholic fatty liver disease (NAFLD):  Syringic acid promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 25/February/2018, 10.36 pm

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to […]
February 19, 2018

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Omeprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 19/February/2017, 11.59 pm

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to […]
February 10, 2018

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Lansoprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 10/February/2017, 11.59 pm

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to […]